Since Judah Folkman hypothesized in 1971 that angiogenesis is required for solid tumor growth, numerous studies have been con- 
INTRODUCTION
In 2001, we published a review about the regulators and clinical applications of angiogenesis. 1 At that time (i) angiogenesis and vasculogenesis were considered to have distinct functions, the latter restricted to embryogenesis; (ii) the role of various growth factors, cytokines, proteases, and extracellular matrix (ECM) molecules in the angiogenesis process was acknowledged, but mechanistic and inhibitor studies largely focused on vascular endothelial growth factor (VEGF); (iii) the targeting of genetically stable endothelial cells (ECs) as opposed to genetically unstable and heterogeneous cancer cells was thought to prevent drug resistance; and (iv) promising mouse xenograft studies raised high hopes for the anticancer potential of antiangiogenic drugs. Since then, the knowledge about (pathological) angiogenesis has increased tremendously: novel insights into tumor vascularization have revealed additional ways to increase intratumoral blood flow. 2 Several new classes of angiogenesis regulators, including proteins involved in axon guidance 3, 4 and bone formation 5 and microRNAs, 6 were found to regulate various aspects of EC biology. EC metabolism, which only recently received attention, has been put forward as the key determinant of angiogenesis regulation. 7 Antiangiogenic agents failed to provide a consistent and lasting antitumor activity in the clinical setting and were even shown to select for more aggressive tumor cell clones. 8 Vessel normalization instead of vessel regression was found to induce a better antitumor response and to improve the delivery and/or activity of radio-and chemotherapy. 9, 10 The aim of this review is to revisit the original paradigms and to highlight insights and concepts in the angiogenesis field that have emerged over the past years. Rather than presenting an exhaustive study of one particular topic, we prefer to give an overview of several recent discoveries in the field, in order to offer an update of current knowledge and thinking about (pathological) blood vessel growth. Accordingly, we mainly refer to papers that have been published after 2000, but occasionally also to older papers that provided seminal contributions to the field. For an in-depth analysis regarding specific concepts we refer to specialized reviews throughout the text.
In particular, this overview focuses on different modes of tumor vascularization (Part 2) and novel angiogenesis regulators and concepts that have been characterized (Part 3). Each type of blood vessel growth displays specific characteristics and molecular regulators, which may underlie treatment failure using VEGF or VEGF receptor (VEGFR) targeting agents. However, the discovery of novel regulatory mechanisms also provides translational promise. The challenges of antiangiogenic therapy, as well as potential ways to translate novel insights into improved therapy will be discussed (Part 4).
MECHANISMS THAT CONTRIBUTE TO INCREASED TUMOR BLOOD SUPPLY
Already in 1971, Folkman hypothesized that solid tumor growth requires angiogenesis, that is, the formation of new blood vessels from preexisting ones. 11 To date, several mechanisms have been shown to contribute to tumor neovascularization, 2 including sprouting angiogenesis, 12 intussusceptive growth (nonsprouting angiogenesis, characterized by the division of vessels by transluminal pillar formation), 13, 14 vascular co-option (hijacking of host capillaries by the tumor), 15 postnatal vasculogenesis (endothelial progenitor cells (EPCs) recruited to the tumor site), 16, 17 and vasculogenic mimicry (VM) (blood vessels lined by tumor cells that mimic ECs, Fig. 1) . 18 F I G U R E 1 Physiological and tumor neovascularization. Physiological neovascularization can occur by sprouting angiogenesis, the recruitment of bone-marrow-derived EPCs that differentiate into ECs (vasculogenesis), or by vessel splitting/intussusception. Tumors can also co-opt preexisting vessels and tumor vessels can be lined by tumor cells instead of ECs (vasculogenic mimicry) or by ECs derived from cancer stem cells (CSCs).
Sprouting angiogenesis
Sprouting angiogenesis was originally defined as a multistep process in which activated ECs (e.g., by proangiogenic factors, such as VEGF) migrate and proliferate to form a new capillary vessel. 1, 11 This process has meanwhile been further dissected, revealing a tight coordination between migratory tip cells and proliferating stalk cells, and the involvement of several recently identified regulators (see also chapter 3).
According to the revised model of sprouting angiogenesis, 12 activated ECs induce the remodeling of the cell-cell junctions and the basement membrane (BM), along with detachment of pericytes (i.e., perivascular support cells). This allows ECs at the leading edge of the sprout to form filopodia and migrate through the ECM in the direction of an angiogenic stimulus. These migrating tip cells are followed by stalk cells, which proliferate to elongate the new sprout, form a lumen, and recruit pericytes for stabilization. Tip cells of two migrating EC fronts connect and fuse (anastomose) to form a perfused vessel. Upon perfusion, ECs become quiescent phalanx cells, which deposit BM and are covered by mature pericytes.
Specification of tip and stalk cells
VEGFR2 is expressed on vascular ECs, where it stimulates EC migration, proliferation, survival, and vascular permeability (reviewed in 19 ). However, recent data obtained by several research groups while studying sprouting in the mouse retina revealed that not all ECs activated by VEGF respond by directed migration and proliferation. In fact, a specification between tip and stalk cells exists that is controlled by a crosstalk between VEGF and Notch, a crucial player in cell-cell communication (reviewed in 20 ).
New sprouts migrate along a chemotactic gradient of VEGF that is produced by the tumor. Consequently VEGF levels are highest at the leading front of the sprout, where activation of VEGFR2 induces the formation of a migrating tip cell. In addition, VEGFR2 signaling causes the expression of the Notch ligand delta-like ligand 4 (Dll4). Dll4-mediated activation of Notch-1 in adjacent ECs suppresses VEGFR2 expression [21] [22] [23] and increases VEGFR1 (a VEGF trap) levels. [24] [25] [26] This renders the cells less responsive to VEGF and promotes the proliferating stalk cell phenotype.
Thus, an activated tip cell prevents its immediate neighbors from adopting the same phenotype. Moreover, at the leading edge, ECs compete for the tip cell position. Cells with higher Dll4 levels and less Notch signaling will be selected as tip cells. 27 Notch signaling also inhibits VEGFR3 expression, a receptor of VEGF-C. VEGFR3 is highly expressed in endothelial tip cells in the retina and intersegmental vessels of the zebrafish, [28] [29] [30] but is downregulated by Notch signaling in the stalk cells. VEGF-C is less potent than VEGF in stimulating tip cell activity but may become more important when VEGF activity is inhibited. Moreover, VEGF-C/VEGFR3 signaling is required for the stabilization of fusing vascular sprouts. 30 Surprisingly, and in contrast to earlier findings, Benedito et al. 31 recently demonstrated that Dll4 protein expression in retinal tip cells is only weakly modulated by VEGFR2 signaling and is even maintained in the absence of VEGFR2.
Moreover, in settings with low Notch activity, Notch was found to upregulate VEGFR3 resulting in strong, ligandindependent angiogenesis, even in the absence of VEGF/VEGFR2 signaling. 32 These context-dependent effects of Notch may contribute to excessive, nonproductive (poorly perfused and hypoxic) angiogenesis that is seen in tumors treated with Notch inhibitors. 33 Clearly, the status of Notch or VEGFR3 activation in the vasculature might be relevant for patients who do not respond to anti-VEGF treatment.
To identify additional regulators of tip and stalk cell fate, the expression profile of tip and stalk cells has been compared. 34, 35 A number of genes are enriched in tip cells, including VEGFR2, platelet-derived growth factor (PDGF)-B, Dll4, matrix metalloproteinase (MMP)14, and the chemokine receptor CXCR4. 35 
Tip cell guidance and vessel anastomosis
Guidance cues are required to direct tip cell migration. This is controlled by several neuronal guidance ligand-receptor interactions (reviewed in 37 ). Neuropilins (Nrp) are nontyrosine kinase receptors that bind to class 3 semaphorins (Sema) and to VEGF. Nrp promote tip cell function by enhancing signaling through VEGFR2 and VEGFR3. [38] [39] [40] Other important regulators of tip cell guidance are SLIT proteins, which are ligands of the roundabout receptors (Robo), and
Ephrins, which activate Eph tyrosine kinase receptors. In particular, ephrin-B2 increases the formation of tip cells and filopodia by regulating VEGFR2/VEGFR3 internalization and trafficking. 41, 42 More information regarding the function of these recently discovered angiogenesis regulators is provided in chapter 3.
When tip cells of two growing sprouts meet, they have to be connected. This process, called anastomosis, requires the establishment of new cell-cell junctions. Vascular endothelial (VE)-cadherin is a calcium-dependent adhesion molecule that controls vascular integrity both in developing and existing vessels. 43 However, VE-cadherin is not only present at endothelial cell-cell contacts but also at the filopodia of the tip cells, suggesting that it is involved in vessel anastomosis. 44 Anastomosis is further facilitated by proangiogenic macrophages, which act as bridging cells between anastomosing tip cells, and secrete angiogenic growth factors and proteolytic enzymes. [45] [46] [47] Notch activation in the macrophages is required for their recruitment to vascular branchpoints and their interaction with endothelial tip cells. 48 
Stalk cell proliferation
As mentioned in Section 2.1.1, Notch activation in stalk cells leads to proliferation arrest. 49 However, proliferation of stalk cells is required to elongate the sprout. This is achieved by the expression of Nrarp (Notch-regulated Ankyrin repeat protein), a negative regulator of Notch signaling that destabilizes the Notch intracellular domain. 50 Expression of Nrarp in stalk cells limits Notch signaling at branch points while promoting Wnt signaling. Wnt, in turn, promotes EC proliferation and vessel stability during sprouting. Interestingly, loss of Nrarp was shown to cause vessel regression. Thus, the balance between Notch and Wnt signaling seems to determine whether new vessels are constructed or destroyed. 51 
Vessel maturation
Finally, a functional vascular network requires maturation at the level of the vessel wall but also at the network level.
In the maturation step, ECs stop migrating and proliferating and the barrier function of vessels is restored. Pericytes play an important role in the stabilization of the nascent blood vessels. They are recruited by PDGF-B, transforming growth factor (TGF)-1, and angiopoietin (Ang)-1. Reduced pericyte coverage leads to leaky, unstable vessels and is associated with metastasis in cancer patients. 52 Vessel maturation is further improved by the deposition of BM around the quiescent ECs, called phalanx cells.
Importantly, in tumors, angiogenic factors remain overexpressed and vessel maturation does not occur, resulting in the typical abnormal and leaky tumor vasculature (reviewed in 53 ). It should also be noted that most insights into tip and stalk cell phenotype and guidance cues have been obtained in developmental rather than tumor models. To explore the full translational potential of these molecular findings, additional studies are required to define the role of these proteins in the cancer setting and, in particular, in metastasis formation.
Intussusceptive microvascular growth (IMG)
Intussusceptive growth or intussusception (i.e., growth within itself) is also known as nonsprouting or splitting angiogenesis. This concept was first reported in 1986 by Caduff et al. 54 in the rapidly expanding postnatal lung vasculature of rats. In this type of vessel formation, the capillary wall extends into the lumen to split a single vessel in two. Using electron and confocal microscopy, Paku et al. proposed a mechanistic model for pillar formation, which involves three consecutive steps. First, intraluminal endothelial bridges are formed. Next, the BM is locally degraded and a bridging EC attaches to a collagen bundle in the underlying connective tissue. This collagen bundle is transported into the vessel lumen by pulling forces exerted by the actin cytoskeleton. Finally, maturation of the pillar occurs by invading pericytes and myofibroblasts, which deposit new connective tissue. 55 Interestingly, this type of blood vessel formation requires only minimal EC proliferation or BM degradation and is therefore less metabolically demanding than sprouting angiogenesis. Moreover, vessels are generated more rapidly by IMG than via sprouting. As such, IMG may have developed to provide a faster response to a tissue's oxygen demand.
IMG has been reported in various tumor types, including colon and mammary carcinoma, melanoma, glioma, and B-cell non-Hodgkin's lymphoma. [56] [57] [58] [59] Sprouting angiogenesis and IMG were even detected simultaneously in a single mammary tumor nodule. 60 Moreover, a switch from sprouting to intussusceptive angiogenesis has been observed in relapsing tumors after irradiation or treatment with antiangiogenic agents (see chapter 4). Since capillaries formed by IMG are less leaky and more stable than the typical abnormal tumor vasculature, IMG could be seen as a mechanism contributing to vessel normalization. 13, 61 Consequently, rapid vascular remodeling induced by IMG could potentially improve drug delivery and radiation efficacy.
Several proteins are suggested to contribute to IMG, including VEGF, 62 PDGF, 63 basic fibroblast growth factor (FGF2), 63, 64 Ang-1, 65, 66 and Erythropoietin. 59, 67 In the chicken chorioallantoic membrane (CAM), VEGF expression was found to be high during sprouting angiogenesis, but reduced during intussusception, 13, 68 suggesting that high concentrations of VEGF mainly induce sprouting, whereas at lower concentrations, a switch to IMG may occur. These data, although obtained in a developmental model, could explain resistance of relapsed tumors after anti-VEGF therapy.
Vascular co-option
Vascular co-option (reviewed in 15 ) is the mechanism by which tumor cells surround and hijack host vessels resulting in the incorporation of host-tissue capillaries by the tumor, thereby eliminating the need for new vessel formation.
As such, tumors that predominantly get their blood supply through vascular co-option are also called nonangiogenic tumors. Since the "hijacked" vessels are normal host vessels, they lack the typical abnormal features of tumor vasculature, thus providing a better intratumoral blood flow. Vessel co-option occurs mainly in highly vascularized tissues, such as liver, lungs, and brain. In primary and metastatic lung cancer and liver metastases even 10-30% of tumors were reported to use this alternative blood supply. Consequently, nonangiogenic tumors that appear in these organs are less likely to respond to antiangiogenic therapy.
Vessel co-option was first extensively studied by Holash et al. 69 after implantation of glioma and mammary adenocarcinoma cells in the rat brain, and in experimental lung metastases of Lewis lung carcinoma cells. Although small tumors were considered to be largely avascular, these authors showed that a subset of tumors rapidly co-opts existing host vessels to form an initially well-vascularized tumor mass. However, rapid regression of these co-opted vessels by increased Ang-2 expression led to an avascular tumor and massive tumor cell death. Ultimately, the tumor was rescued by VEGF, which in concert with Ang-2 induced robust angiogenesis at the tumor periphery. 70 Following studies
showed that VEGF-overexpressing human melanoma cells induced rapidly growing brain metastases by dilation of coopted, preexisting vessels. 71 Vessel co-option has also been demonstrated in non-small cell lung cancer (NSCLC) and lung metastases, derived from breast, colorectal, and renal cancer cases. [72] [73] [74] [75] A prerequisite for nonangiogenic tumor growth in the lungs appears to be the ability of the tumor to preserve the parenchymal structures of the lung, which can easily be distinguished on tissue sections. 73 In liver metastases of colorectal carcinomas (CRC), tumor cells were found to replace hepatocytes, preserving the liver architecture and co-opting the sinusoidal blood vessels. 76 This replacement pattern was even more prevalent in breast carcinoma liver metastases, both at the tumor edge and center, and was not accompanied by induction of hypoxia or vascular leakage. 77 The above-mentioned studies indicate that, at least in well-perfused organs, tumors may grow without the need for new blood vessel formation. However, research conducted on this type of alternative blood supply has been limited, mainly because of difficulties to identify co-opted vessels in the tumor vasculature and to distinguish them from vessels that have been formed through angiogenesis. Most studies use CD31, CD34, or vWF staining to quantify angiogenesis.
However, these markers also stain co-opted vessels. Smooth muscle cell actin (SMA), which stains pericytes that cover mature vessels, may better distinguish between co-opted and angiogenic vessels since the latter are less mature and often lack pericyte coverage. 78 Double immunostaining using an EC marker and an antibody against Ki67 or proliferating cell nuclear antigen (PCNA) that detects proliferating cells may also aid in the detection of ongoing angiogenesis.
Alternatively, phase contrast magnetic resonance imaging has been shown to detect vascular remodeling in co-opting brain. 79 In conclusion, additional studies are warranted to understand the mechanism of vascular co-option and to investigate its impact on antiangiogenic tumor therapy and recurrence of liver, lung, or brain metastases. In particular, since co-opted vessels are structurally diverse from angiogenic vessels they are likely to be differentially regulated.
It may therefore be expected that these vessels do not respond to the factors that drive angiogenic blood vessel growth. The latter is also reflected by increased co-option occurring in tumors resistant to antiangiogenic therapy (see chapter 4).
Role of EPCs in tumor neovascularization
Accumulating data indicate that EPCs are not only involved in embryonic development but also in adult vasculogenesis (reviewed in 16, 17, 80 ). This concept was first demonstrated by Asahara et al. in 1997, 81 who isolated circulating cells with properties of progenitor and ECs from human peripheral blood. These cells (i) differentiated into ECs in vitro and
(ii) contributed to angiogenesis in a mouse model of hind limb ischemia, and were therefore considered to be EPCs. A subsequent study by these authors showed that bone marrow EPCs not only have therapeutic potential but are also involved in tumor neovascularization. 82 The role of EPCs and vasculogenesis in cancer has since then been extensively studied.
In physiological conditions, EPCs are maintained in the bone marrow. They reside in a "stem cell niche" exposed to high local concentrations of the chemokine stromal cell-derived factor 1 (SDF-1/CXCL12), which attracts and binds CXCR4-expressing EPCs. 83 Also, integrins are involved in the retention of EPCs in the bone marrow. In particular, integrin 4 1 mediates adhesion of EPCs to fibronectin and vascular cell adhesion molecule (VCAM)-1. 84 The mobilization of EPCs from the bone marrow to the peripheral blood and the tumor site is regulated by various cytokines and proteolytic enzymes that are released from the tumor microenvironment. [85] [86] [87] So far, VEGF/VEGFR and CXCL12/CXCR4 are considered the key pathways regulating bone marrow-EPC mobilization. 85, 86 The EPC-mobilizing activity of both cytokines is dependent on MMP9, whose expression is induced by VEGF. In the initial step of EPC mobilization MMP9 induces the release of EPCs into the circulation. 85 VEGF-induced mobilization of EPCs also involves downregulation of 4 1 integrin in the bone marrow. 88 EPCs migrate to sites of vascular damage, where they increase vascularization and improve blood flow. Increasing numbers of circulating EPCs have also been observed in many cancers, including some types of leukemia, lymphoma, and breast cancer. 16 The migration of EPCs to the tumor site is dependent upon chemokine gradients. Once in the tumor bed, EPCs may either differentiate into ECs or stimulate tumor angiogenesis by producing proangiogenic factors.
However, the exact role played by EPCs in tumor angiogenesis remains unclear. In particular, the number of EPCs incorporated into nascent tumor vessels varies between 50% to undetectable. These differences are most likely related to the lack of a consensus definition of EPCs. Indeed, EPCs share many markers with hematopoietic stem cells, both cell linages deriving from a common progenitor, the hemangioblast (for more information see 16 
Vasculogenic mimicry
VM refers to the plasticity of cancer cells to form vascular channels. Consequently, tumor cells are directly exposed to the blood, thus facilitating tumor cell invasion and dissemination. Increased metastasis may explain the correlation between VM formation in malignant tumor tissue and poor patient clinical outcome. 89 VM was first described in 1999
by Maniotis et al. 90 in aggressive metastatic melanoma and has since then been reported in a variety of tumors, including various carcinomas, sarcomas, glioblastomas, astrocytomas, and melanomas. 89 In melanoma and glioblastoma the intratumoral hypoxic microenvironment was suggested to induce the phenotypic switch to VM. 91, 92 Tumor cells that contribute to VM present a multipotent phenotype. However, unlike embryonic stem cells, these cells lack critical checkpoint regulation, rendering them highly aggressive. 93 Using microarrays it was demonstrated that melanoma cells that line VM channels show characteristics of both malignant and ECs. 94 Recent studies even indicate the involvement of cancer stem cells (CSCs) in VM (see Section 2.6).
Remodeling of the ECM is critical for the formation of VM channels and to connect these tumor cell-lined vessels to the ECs of the host vasculature. In particular, the metalloproteinases MMP2 and MMP14 are crucial for VM formation by promoting the cleavage of the laminin-5 2-chain into fragments that stimulate migration and invasion. 95 One of the first proteins that was shown to be involved in VM in aggressive melanoma is VE-cadherin. VE-cadherin phosphorylates the epithelial-associated kinase EphA2 (see chapter 3), which increases MMP production. Accordingly, knockdown of VE-cadherin or EphA2 inhibits VM. 96, 97 In vivo data attribute an important role for VEGF in VM formation. In melanoma, VEGF/VEGFR1 and downstream PI3K signaling act in co-operation with integrin-mediated signaling pathways to induce VM. 98 In ovarian cancer, VM is mediated by VEGF-induced expression of EphA1, MMP2, and MMP9. 99 In conclusion, VM has been reported in many tumor types and its occurrence is associated with poor clinical prognosis. However, the study of VM is hampered by the lack of methods to clearly distinguish VM vessels from normal EC lining. Besides the fact that these tumor-derived ECs still express some tumor-specific markers, they are indistinguishable from ECs. As such, it has been difficult to link antiangiogenic treatment failure to the appearance of VM-type vessels. Recent data, which show the involvement of hypoxic, angiogenic, and stem cell pathways (see Section 2.6) in VM formation, indicate that VM-containing tumors might be more sensitive to broad-acting drugs compared to specific VEGF-targeting agents. In fact, an in vitro differentiation assay suggested that hypoxia, but not VEGF, is an important factor in the differentiation of glioblastoma multiforme (GBM) tumor cells to ECs. 92 
Role of CSCs in tumor neovascularization
CSCs are considered to be major drivers of tumor progression due to their self-renewal capacity and limitless proliferative potential. However, these cells may also promote tumor vascularization by increasing EPC recruitment. A comparison of rat glioma xenografts containing a high and low fraction of CSCs showed that CSC high tumors express increased levels of VEGF and CXCL12, which promote the mobilization and recruitment of EPCs. 100 CSC-high tumors also displayed an increased microvessel density (MVD) and blood perfusion. In vitro, CSC-high cultures induced higher levels of EC proliferation and tube organization compared with CSC-low cultures.
Recent studies even raised the possibility that CSCs may also differentiate to ECs and give rise to true endothelial linings in some human cancers, including lymphoma and glioblastoma. 101, 102 This hypothesis was supported by the fact that a subpopulation of ECs within glioblastomas harbors the same somatic mutations as tumor cells, such as amplification of the epidermal growth factor receptor (EGFR). 101 Moreover, a fraction of CD133 + stem cells is multipotent and capable of differentiating into tumor and endothelial lineages. Selective targeting of ECs generated by glioblastoma stem-like cells (GSCs) in mouse xenografts resulted in tumor reduction, indicating the functional relevance of the GSC-derived endothelial vessels. 102 Moreover, Cheng et al. 103 elegantly demonstrated that CSCs may also differentiate into pericytes. Analysis of human GBM specimens using lineage-specific fluorescent reporters showed that most pericytes are derived from neoplastic cells. These GSCs are recruited to ECs by CXCL12/CXCR4 signaling and differentiate into pericytes by TGF-. In addition, elimination of GSC-derived pericytes disrupted the vasculature in GBM, resulting in reduced tumor growth. 103, 104 CSCs, as identified by expression of the stem cell markers CD133 and CD44 (VE-cadherin), also directly increase vascularization by VM in aggressive renal cell carcinoma. 105 CD133 expression further correlated with VM in triplenegative breast cancer specimens 106 and the GBM cell line U87. 107 The mechanism by which CSCs induce VM is not yet completely understood, but the VEGF/VEGFR2 and Nodal/Notch pathways seem to be involved. 107,108
NOVEL ANGIOGENIC REGULATORS AND CONCEPTS
The molecular dissection of angiogenesis mechanisms has led to the discovery of novel types of angiogenesis regulators ( Fig. 2) , including proteins involved in bone formation and neurovascular guidance. Meanwhile, microRNAs were discovered and found to regulate various aspects of EC biology. Finally, EC metabolism has been put forward as the main engine that drives angiogenic processes. These concepts will be highlighted here.
Bone morphogenetic proteins (BMPs)
BMPs belong to the TGF superfamily and consist of about 20 proteins that regulate multiple biological processes in development and morphogenesis. 5 BMPs are synthesized in the cytoplasm as dimeric precursor proprotein complexes, which are cleaved by serine endoproteases before secretion. 109, 110 BMP signaling is mediated by heteromeric combinations of type 1 (ALK1 /SKR3, ALK2/ACTRIA, ALK3/BMPRIA, and (PI3K)-Akt-mTOR pathway, the small GTPases Rho, Rac, and Cdc42, and the Ras-Erk-Mitogen-activated protein kinase (MAPK) pathway. 111, 112 BMP signaling may be affected by membrane-associated coreceptors including Bambi, DRAGON, ROR2, Endoglin, and Betaglycan (TbetaRIII). [113] [114] [115] The latter two lack kinase activity but regulate vascular development by increasing the binding of BMPs and by modulating BMP receptor trafficking and cell localization. 116, 117 Beyond their importance in embryonic development, BMPs exert proangiogenic roles in vitro and in vivo directly by activating ECs, or indirectly by inducing the expression of other proangiogenic factors. BMP2/4/6/7 stimulate ECs to proliferate, migrate, and to reorganize in tube-like structures via the activation of SMAD1/5, Erk 1/2, and Id1 expression. [118] [119] [120] [121] In vivo, recombinant BMP2/4 enhance angiogenesis in the chicken CAM assay and in Matrigel plugs.
BMP2/4 further induce a large increase in the size and number of blood vessels in different murine tumor models, acting early in the establishment of a tumor's blood supply. 122, 123 In several physiological and pathological conditions BMPs influence the vasculature in an indirect way by regulating the expression of growth factors and their receptor(s) including VEGF, FGF, VEGFR2, and VEGFR1. [124] [125] [126] BMP9 and BMP10 instead mainly mediate the late phases of angiogenesis, as they suppress EC migration and proliferation. 118 These BMPs are functionally equivalent ligands of the endothelial-specific receptor ALK1. They are supplied via the bloodstream (2 and 12 ng/mL in healthy humans) and are in constant interaction with the apical side of ECs where they control quiescence of adult blood vessels. [127] [128] [129] [130] During embryogenesis, two distinct functions of BMP10 have been described. BMP10 supports vascular development via ALK1-dependent signaling in ECs, which can be functionally substituted by BMP9. On the other hand, BMP10 regulates heart development in a BMP10-exclusive manner. In postnatal vascular development both ligands serve a redundant role. 131, 132 BMP9 and BMP10 prevent VEGF and FGF2-induced sprouting angiogenesis in vitro and in several in vivo assays, including Matrigel plug assay, CAM assay, and developmental retinal neovascularization in vivo via activation of downstream SMAD 1/5 pathways. 133 BMP9 not only inhibits angiogenesis but also destabilizes already formed vessels. 130 Moreover, the BMP9/ALK1 pathway inhibits neovessel formation in mouse models of age-related macular degeneration. 134 Recently, particular attention was reserved to BMP9/10-ALK1 signaling as an alternative target for the development of antiangiogenic therapies (reviewed in 135, 136 ). ALK1 is widely expressed on prostate, skin, thyroid, kidney, ovary, lung, pancreas, and liver tumor blood vessels. Anti-ALK1 can decrease tumor growth and angiogenesis when combined with a VEGFR inhibitor in a human/mouse chimera tumor model. 137 Two main pharmacological inhibitors, an ALK1-Fc fusion protein (Dalantercept/ACE-041), [138] [139] [140] which serves as BMP9 (and BMP10) ligand trap, and a fully human antibody against the extracellular domain of ALK1 (PF-03446962) [141] [142] [143] are currently under clinical development for cancer treatment.
The neurovascular link: Axon guidance molecules
While studying the angiogenic process at a molecular level, a strong resemblance was noted between vessel sprouting by tip cells and neural development/axon guidance. Four canonical families of axon guidance cues implicated in tumor angiogenesis are distinguished: netrins, which binds distinct receptor types (deleted in colorectal cancer (DCC) or UNC5 homologs); semaphorins, which bind plexins and neuropilins; Ephrins-Ephrin receptors (Eph); and Slitsroundabout receptors (Robos). 3, 4 Here we focus on their function in (tumor) angiogenesis.
Although the netrins were the first axon guidance molecules to be identified, the role of netrin 1 and netrin 4 in angiogenesis has yet to be understood since contradictory results have been obtained in vitro and in vivo. 144, 145 Besides, expression of netrin 1, the most studied netrin, has only been demonstrated in few tumors, although its receptor UNC5B is strongly expressed in tumor blood vessels. 144
Slits and robo receptors
Slits are secreted ECM proteins that share a high degree of structural conservation. In mice and humans three Slits have been identified (Slit1, Slit2, and Slit3). 146 In order to gain axon guidance function Slits need to be proteolytically cleaved to release the active Robo-binding N-terminus. 147 The effect of SLIT processing on endothelial receptor activation is not yet clear. 148 The Robo family of receptors is highly conserved through evolution. In mammals four Robo receptors are present:
Robo1/Dutt1, Robo2, Robo3/rig1, and Robo4/magic roundabout. 146 While Robo1-3 contain a high degree of structural and functional similarity, the extra-and intracellular domain of Robo4 is smaller and Robo4 acts distinctly. 3 Robo receptors belong to the immunoglobulin (Ig) superfamily of cell adhesion molecules. The extracellular domain of Robo1-3 interacts with the Slits, whereas Robo4 requires a coreceptor as it does not directly bind Slit ligands. This coreceptor might be a heparan sulfate proteoglycan (e.g., Syndecan), Robo1, Robo2, or UNC5B (the chemorepellent receptor of Netrin-1). [149] [150] [151] [152] Proteoglycans also stabilize interactions between Slits and Robo1-3 and heparan sulfate glycosaminoglycans concentrate and localize Slits in the tissue. 153, 154 Robo1 and Robo4 are expressed in ECs and regulate both physiological and pathological angiogenesis. 155 Robo4 −/− mice display normal vessel patterning. 152, 156 However, during pregnancy, Slit/Robo4 signaling is involved in regulation of the vascular network in the mammary gland when angiogenesis is stimulated by VEGF. 155 The proangiogenic action of VEGF is in this process balanced by Slit/Robo4 interaction, through inhibition of lamellipodia formation. 157 Robo4 maintains the barrier function of mature vessels by inhibiting angiogenic factor-induced endothelial hyperpermeability. 156 Consequently, high expression of Robo4 correlates with a favorable prognosis in early-stage lung cancer. 158 Slit2 signaling through Robo1 and Robo2 mediates pathological retinal neovacularisation. 159 Blockade of Robo1 by a neutralizing antibody reduces MVD and tumor growth of xenografted melanoma cells 160 and chemical-induced squamous cell carcinogenesis. 161 Whereas normal and hyperplastic buccal mucosa express Slit2 minimally, its expression is drastically upregulated in neoplastic mucosa where it correlates with increased tumor angiogenesis. 161 Slit2 mRNA is expressed in multiple human cancer cell lines and in cancer tissue. 160 The promoter region of Slit2 is frequently hypermethylated in lung and breast cancer reducing Slit2 expression and suggesting a tumor-suppressive role for Slit2. 162 Thus, Slit2 affects both endothelial and tumor cells and may elicit endothelial stimulatory as well as inhibitory actions. This attracting versus repellent action is typical for members of the axon guidance family. In the case of Slits it is at least partly caused by differential receptor activation. Robo1, which directly interacts with Slits, promotes endothelial motility. 150 In contrast, Robo4 that needs a coreceptor for Slit-induced signaling induces endothelial repellence and, in counteraction of VEGF, provides vascular stabilization. 156, 163 In addition to differential expression or activation of Robo1/2 versus Robo4 on ECs, other explanations have been proposed for the angiogenic versus angiostatic effect of Slits 148 : (1) the need for a cofactor enforcing the angiostatic effect, 147, 164, 165 (2) agonistic versus antagonistic effects of the N-terminal fragment of Slit versus full-length Slit, and (3) a celldependent processing of Slit. 147, 164 Additional research on Slit2/Robo signaling in ECs will hopefully provide a unified concept. 148 Thus, based on their altered expression in a wide variety of cancer types and their regulatory function on vascular networks, Slits and Robos might serve as targets for cancer treatment. However, their bifunctionality, that is, opposite functions depending on the cellular circumstances, represents a major challenge. In addition, careful drug targeting to the tumor will be needed, because interruption of normal Slit/Robo signaling in nearby tissues could have deleterious effects. 146
Plexins, neuropilins, and semaphorins
Like Slit proteins, semaphorins are multifaceted regulatory signals involved in physiological and pathological angiogenesis. Their receptors are expressed on tumor cells, monocyte/macrophages, and ECs in the tumor stroma. As regulators of tumor angiogenesis, tumor growth, cancer cell invasiveness, and metastatic spreading, they are potential therapeutic targets in cancer.
In vertebrates, the semaphorin family contains around 20 genes that are classified based on common structural features of the encoded proteins. 4, 166 All semaphorins contain a typical sema domain, harboring sites for semaphorin dimerization and receptor binding, which is located close to the N-terminus. This domain is also present in the semaphorin receptors of the plexin family. Class 3 semaphorins are secreted, whereas other semaphorins are membrane-anchored or transmembrane proteins that can be further processed into soluble forms by specific proteases. The active forms of several class 3 and class 6 semaphorins are homodimers. [167] [168] [169] Plexins are the main receptors for semaphorins, but a subset of the class 3 semaphorins requires the presence of obligate coreceptor molecules, called neuropilins (Nrp1 and Nrp2). 4 The latter are also coreceptors for VEGFs.
Plexins are devoid of TK activity, but are able to activate RTKs (including VEGFR2, FGFR2, and EGFR) in "trans." 170 Multiple semaphorins have been associated with modulation of the tumor vasculature (recently reviewed by 166 , including Sema3A, Sema3E, Sema3F, and Sema3G (as inhibitory signals) and Sema4D and Sema6D (as proangiogenic factors)).
Sema3A is an inhibitor of developmental angiogenesis. 171, 172 Downregulation of its expression in many types of solid tumors annihilates its negative impact on angiogenesis. [173] [174] [175] Also angiostatic Sema3F is downregulated during tumor progression. [175] [176] [177] Systemic and tumor-targeted delivery of Sema3A stabilizes the tumor vasculature and inhibits tumor angiogenesis, metastasis, and tumor growth in multiple mouse models, supporting further investigation of Sema3A-based anticancer therapy. 178 Some semaphorins seem to control the recruitment and activation of leukocytes. Soluble Sema4A and Sema7A chemoattract and activate monocytes/macrophages inducing the release of proinflammatory and proangiogenic molecules (e.g., CXCL8 or VEGF). [179] [180] [181] Usually, semaphorin signaling pathways lead to inhibition of migration, 4 however, Sema4D/CD100 and Sema6D are angiogenic. Sema4D is a membrane-bound protein expressed in tumor cells, tumor-associated macrophages (TAMs), 182 and platelets, but the extracellular domain can be cleaved and released from producer cells by MMPs. Soluble Sema4D retains the biological activity of membrane-bound Sema4D. Binding of Sema4D to plexin-B1 stimulates angiogenesis directly through activation of plexin-B1 and the downstream signaling pathways PI3K/Akt, Rho, and NFkB, and indirectly via transactivation of the hepatocyte growth factor (HGF) receptor Met. 183 Angiogenic Sema6D signals through Plexin-A1, which forms complexes with, and activates, VEGFR2. 184
Ephrins and ephrin receptors (Eph)
The Eph (erythropoietin-producing hepatocellular carcinoma) receptors, which are TKs, and their membrane-anchored ephrin (Eph receptor interacting protein) ligands form two large families. 185, 186 Ephrin-A ligands are attached to the cell membrane via a glycosylphosphatidyl-inositol (GPI) linker, whereas ephrin-B ligands are transmembrane proteins.
The receptor-ligand interactions are highly promiscuous. 187 Strong genetic evidence supports an essential role for ephrin-B2 and EphB4 in the development of blood and lymph vessels during embryogenesis. [188] [189] [190] [191] In addition, ephrin-B2 assists in stabilization of vessel walls during vascular maturation allowing cell spreading and focal adhesion. 192 Besides regulating embryonic vessel formation, ephrin-B2 and EphB4 play a role in neovascular eye disorders. 185 Furthermore, several Eph receptors and ephrin molecules are upregulated in tumors and may affect tumor growth and vascularization. For instance, EphA2 and its ligand ephrin-A1 are expressed in breast, ovarian, prostate, lung, and skin cancer. 187, 193 In breast tumor cells overexpressing EphA2, EphA2 signals in a ligand-independent fashion through crosstalk with EGFR and HER2, thereby promoting tumor growth. 194 In the tumor environment, expression of EphA2, which is absent on quiescent vasculature, is induced in ECs via interaction with ephrin-A1 present on tumor ECs and tumor cells. Subsequent forward signaling through EphA2 stimulates angiogenesis 195 and vascular permeability. 196 Blocking EphA receptor activation or gene deletion in mice reduces the size and vascularization of experimental tumors. 197 Similarly, high expression of ephrin-B ligands and EphB receptors in some human cancers correlates with poor prognosis. 198, 199 Ephrin-B2, which is upregulated in ECs by hypoxia and VEGF, is expressed on the blood vessels of many tumors. 195 Through activation of ephrin-B2 on ECs, tumor cell expressed EphB4 promotes angiogenesis. 200 Several approaches targeting the activity of ephrin-B2 and/or EphB4 reduced the growth and vascular network of tumors. 201, 202 However, certain Eph receptors exert tumor-suppressive activity 203 and therefore more research is needed to exactly decipher the signaling pathways and activities of Ephs and ephrins in specific cell or cancer types.
miRNAs as master regulators of tumor angiogenesis
MicroRNAs (miRs) are short (∼22-nucleotides in length) endogenous noncoding RNAs that were discovered in vertebrates in 2001. 204 They negatively regulate the expression of target genes at a posttranscriptional level, thereby affecting many cellular processes. 205, 206 MiRs promote the cleavage of the target mRNA or inhibit its translation through complementary base pairing at the 3 ′ untranslated region (UTR). 207 Expression of miRs is strictly regulated in Table I and reviewed in 6 ).
MiRs targeting proangiogenic factors are typically downregulated in cancer, whereas angiogenic miRs reduce angiostatic proteins. As such, both can contribute to the angiogenic switch during cancer progression. Interestingly, miR expression may be transcriptionally controlled by (anti)angiogenic proteins, adding further complexity to miR-based angiogenesis regulation.
Endothelial-specific miRs: miR-126
Some miRs are endowed with tissue-specific actions. A crucial player in EC biology is miR-126, which is specifically enriched in ECs and EPCs. During embryonic vasculogenesis, miR-126 maintains vessel integrity by enhancing the proangiogenic activity of VEGF and FGF, via suppression of negative regulators of the Ras/MAPK and PI3K/Akt pathways. 260, 261 However, miR-126 also binds to the 3 ′ UTR of VEGF mRNA, thereby reducing the expression of VEGF. 247 As such, its role in tumor growth is not clear and, depending on the tumor type, it may elicit a tumorpromoting or suppressing function (reviewed in 262 ).
miR-126 is downregulated in several cancer types, including lung, 263 breast, 264 colorectal, 265 and gastric cancer 247 by promoter methylation of its host gene, EGF-like domain 7 (Egfl7). 265, 266 A correlation was shown between miR-126 downregulation and poor metastasis-free survival of breast cancer patients. 266 Moreover, downregulation of miR-126 was found to correlate with increased MVD and VEGF expression in gastric cancer tissues. 247 Conversely, miR-126 was shown to suppress EC recruitment to metastatic breast cancer cells, metastatic angiogenesis, and colonization through coordinate targeting of novel proangiogenic genes and biomarkers of human metastasis (i.e., insulin-like growth factor binding protein 2, PITPNC1, and c-Mer tyrosine kinase). 267
Cell-type and context-dependent miR: miR-17-92
The miR-17-92 cluster was among the first miRs that were linked to tumor angiogenesis. with downregulation of TSP-1. 268 Recently, treatment of ECs with VEGF was shown to trigger the expression of all miR-17-92 cluster members by activation of MAPK and the transcription factor Elk-1 (member of the E26 transformationspecific (ETS) oncogene family), which binds to the miR-17-92 cluster promoter sequence. This resulted in repression of PTEN (phosphatase and tensin homolog), a tumor suppressor that inhibits Akt/PI3K signaling. Consequently, VEGFinduced miR-17-92 cluster expression contributes to the angiogenic switch of ECs and was found to be essential for EC proliferation and sprouting. 271 However, in an in vivo setting, miR-17-92 biology is likely to be more complex, and dependent on the regulation of individual (pro-and antiangiogenic) members of this cluster as well as non-EC-derived miR-17-92 cluster members.
Indeed, miR-17-92 also elicits antiangiogenic activity by targeting TGFBR2, VEGF, and the transcription factor hypoxiainducible factor (HIF)-1 in colorectal cancer. 223 Moreover, whereas miR-17/20 exhibits antiangiogenic activity in ECs, it does not affect tumor angiogenesis, indicating a context-dependent regulation. 272 
miRs Regulate Cellular Adaptation to Hypoxia
Further experimental evidence suggests that miRs are important components of cellular adaptation to hypoxia. A number of miRs are upregulated by HIF-1 . The predominant hypoxia-inducible miR is miR-210. HIF-1 binds to a hypoxiaresponse element (HRE) on the proximal miR-210 promoter. MiR-210 target genes can be classified into five major functional categories: mitochondrial metabolism, cell cycle control, angiogenesis, apoptosis, and DNA damage repair.
Expression of this hypoxamiR is greatly induced in pancreatic, breast, head and neck, lung, colon, and renal cell lines after exposure to hypoxia. 273 Furthermore, miR-210 expression has been linked to bad prognosis in patients with soft tissue sarcoma, breast, head and neck, and pancreatic cancer (reviewed in 274, 275 ). miR-210 also emerged as a potential therapeutic target in diffuse large B-cell lymphoma. 276 Whereas miR-210 is widely expressed, other miRs respond to decreased oxygen tension in a more tissue-specific manner. Moreover, HIF-1 expression itself is regulated by several miRs, such as miR-497 in breast carcinoma, 224 adding another level of complexity to the classic hypoxia-regulated gene network.
EC Metabolism
The role of EC metabolism in tumor angiogenesis has been completely overlooked during the past 40 years. Still, recent concepts indicate that angiogenesis is not only regulated by the balance between pro-and antiangiogenic factors, but also by changes in EC metabolism (reviewed in 7 ). Indeed, activated ECs rapidly switch from quiescence to angiogenic sprouting and must be able to adjust their metabolism accordingly. Thus, metabolic changes may significantly impact EC behavior and activity.
Glucose metabolism
Despite their privileged position having direct access to oxygen in the blood, ECs from macro-and microvessels rely primarily on glycolysis (generating around 85% of their ATP content through this pathway) rather than on mitochondrial respiration to generate energy. 277 In particular tip cells need a high rate of glycolysis.
Glucose enters ECs via glucose transporters (GLUTs) and is converted to pyruvate by a cascade of glycolytic enzymes. Proangiogenic signals like VEGF and FGF2 increase the expression of GLUT-1 as well as that of main glycolytic enzymes, such as PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3). Moreover, PFKFB3
harbors hypoxia-response elements and is a target of HIF-1 . Accordingly, knockdown of PFKFB3 in ECs reduces vascular sprouting by impairing tip cell migration and stalk cell proliferation, without affecting the expression of angiogenic factors. 277, 278 Glycolytic intermediates may also be shuttled into other metabolic pathways, including the pentose phosphate pathway (PPP) and hexosamine biosynthesis pathway (HBP). The PPP pathway uses glucose-6-phosphate to generate NADPH for redox control and lipid synthesis and ribose-5-phosphate for nucleotide synthesis. Tumor ECs upregulate genes involved in nucleotide synthesis and shunt glucose metabolites to nucleotide pathways to assure sufficiently high nucleotide pools for cell duplication. NADPH reduces oxidized glutathione, a key cellular oxidant, thereby protecting ECs against oxidative stress. 279 The HBP pathway produces N-acetylglucosamine for protein O-and N-glycosylation.
Posttranslational glycosylation status determines the activity and structure of several angiogenic proteins, including Notch, 280 VEGFR, 281 and MMPs. 282 Each of these pathways is important for angiogenesis as its genetic or pharmacological inhibition reduces EC viability, migration, and/or angiogenesis. 280, [283] [284] [285] In addition, recent findings highlight the inhibition of c-MYC mediated by FOXO1 (Forkhead box protein O1) as a key mechanism that decelerates metabolic activity of ECs and controls quiescence. MYC ablation impairs glycolysis, mitochondrial function, and proliferation of ECs. Conversely, EC-specific overexpression of MYC fuels these processes, and restoration of MYC signaling in FOXO1-overexpressing endothelium normalizes metabolic activity and branching behavior. 286
Fatty acid metabolism
Besides glucose, fatty acids (FAs) represent an important fuel source for ECs. FAs enter the cell through different mechanisms, including membrane-associated FA transport proteins (FATPs), and associate with cytosolic FA-binding proteins (FABPs), which chaperone FAs inside the cell. 287 Proangiogenic signals (VEGF and FGF2) upregulate the expression of FATPs and FABPs, which are required for EC proliferation and sprouting. 288 Recently it has been clarified that, unlike in most normal and cancer cell lines, FA oxidation (FAO) contributes minimally (less than 5%) to ATP synthesis in ECs. Instead, FAO provides carbons for de novo nucleotide synthesis via the tricarboxylic acid (TCA) cycle, thereby promoting EC proliferation and sprouting angiogenesis. 289 Carnitine palmitoyltransferases (CPTs), more precisely CPT1, catalyze the transesterification of long-chain FA-CoA and its transport into the intramitochondrial matrix, thus regulating the rate of FAO. CPT1A is the most abundant isoform in ECs. Its deficiency impairs sprouting and proliferation without altering ATP levels or oxygen consumption. 289 In conclusion, recent data indicate that metabolic reprogramming, a crucial hallmark of cancer that shifts metabolic pathways to enable sustained growth of cancer cells, also applies to tumor ECs. Consequently, blocking the EC engine might prove more effective than blocking individual drivers, such as VEGF. However, it should be noted that energy production depends on nutrient availability. As such, EC metabolism is modulated by the metabolic program of other cell types in the tumor microenvironment. Accordingly, recent data show that hypoxic TAMs compete with tumor ECs for glucose. 290 
ANGIOGENESIS IN PRACTICE: CLINICAL IMPLICATIONS
The clinical usage of antiangiogenic agents targeting VEGF/VEGFR has shown that the anticancer potential of these drugs is limited and associated with unexpected side effects and tumor resistance, or even the occurrence of more aggressive tumor cells and increased metastasis. Accumulating evidence indicates that these adverse effects may be induced by the expression and activation of alternative angiogenic factors and pathways, the appearance of hypoxiatolerant or vessel-independent tumor cells or a tumor vasculature that arises in the absence of angiogenesis. Moreover, as novel mediators continue to be discovered, it is clear that the multifactorial nature of neovascularization requires tackling the process at different levels. Various resistance mechanisms and potentially improved treatment options and/or schedules will be discussed here.
Why antiangiogenic therapy fails to treat cancer
During the past 10 years, angiogenesis inhibiting drugs have been tested (i) in the adjuvant setting after surgical removal of the primary tumor to prevent local relapse or the growth of micrometastases or (ii) in the neoadjuvant setting to downsize nonresectable to potentially resectable tumors. In most settings, antiangiogenic agents such as bevacizumab and aflibercept (which are classical VEGF-traps) only showed significant activity when combined with cytotoxic chemotherapy, while tyrosine kinase inhibitors (TKIs) also worked as single agents.
Despite the increasing number of data and drug candidates, resistance to antiangiogenic therapy remains a challenging issue that is associated with variable success in the clinic and with poor prognosis for cancer patients. Several mechanisms can account for this therapeutic failure. 291
Activation of alternative proangiogenic pathways
Besides VEGF, several additional pathways are implicated in tumor growth and cancer-associated angiogenesis.
These alternative ways can sustain tumor growth and blood vessel survival even in response to VEGF/VEGFR blockade.
Inhibition of VEGFR2 in a mouse model of pancreatic cancer resulted after an initial response in tumor regrowth, accompanied by increased vascularization and augmented levels of proangiogenic factors like FGF2, Ang-1, and ephrin-A1. 292 Likewise, FGF2, CXCL12, and placenta growth factor (PlGF) were upregulated in progressive glioblastoma growth after treatment with the pan-VEGFR TKI AZD2171. 293 Together with the "alternative" proangiogenic factors mentioned above several other players have been identified in preclinical studies such as EGF, FGF1, Dll4, HGF, CXCL8, and PDGF-C. 294 Accordingly, increased serum levels of FGF2, HGF, PlGF, and CXCL12 have been observed in patients treated with antiangiogenic agents just before tumor progression and acquisition of resistance. 295 These observations reinforce the rationale for simultaneous targeting of multiple angiogenic drivers. However, the majority of TKIs used to treat patients are multitargeting drugs that nevertheless failed to treat different types of tumors. 296,297
Recruitment of proangiogenic stromal cells
The tumor microenvironment contains a heterogeneous and complex mixture of stromal cells (fibroblasts, pericytes, endothelial, mesenchymal, and hematopoietic cells) that actively support tumor growth and are associated with resistance to anti-VEGF therapy. 298 Antiangiogenic as well as vascular disrupting agents (VDAs), which cause acute hypoxia, trigger the recruitment of EPCs and immune cells to the tumor margins. Various preclinical models strongly suggest a role for neutrophils in mediating tumor angiogenesis and refractoriness to anti-VEGF therapy. Tumor-associated neutrophils (TANs) mediate the angiogenic switch in different tumor models, by producing various growth factors (including VEGF) and secreting active MMP9 that releases FGF2 and VEGF from the ECM. 299 Also the clinical evidence supporting this notion is growing. In myxofibrosarcoma patients, elevated numbers of neutrophils positively correlate with tumor MVD. Moreover, intratumoral infiltration of neutrophils is significantly associated with tumor grade in glioma patients. 300 In NSCLC patients treated with chemotherapy plus bevacizumab, a high number of circulating neutrophils and monocytes and a high neutrophil-to-lymphocyte ratio are associated with poor clinical outcome. 301 In the last decade a tumor-promoting role has also been attributed to TAMs. Despite their potential role in antitumor immunity, high frequencies of TAMs correlate with poor prognosis in most human cancers. 302 TAMs have proangiogenic activity, and macrophage infiltration in tumors is generally associated with high vascular density. 303, 304 Indeed, TAMs infiltrating established tumors acquire an "M2-like" phenotype endowed with promotion of tumor growth and angiogenesis, remodeling of tissues, and suppression of antitumor immunity. 304 M2-like TAMs accumulate in hypoxic tumor areas and display strong proangiogenic activity through the expression of various angiogenic growth factors, cytokines, and proteases. 305 Furthermore, many other stromal subpopulations may be present or recruited at the tumor site during tumor growth or in response to antiangiogenic treatment. In particular, immature myeloid cells or EPCs that produce growth factors or physically incorporate into tumor blood vessels have been detected in the tumor microenvironment, where they may foster resistance to antiVEGF therapy. 306,307
Alternative mechanisms of tumor vascularization
As mentioned in Chapter 2, tumor vascularization may occur through different mechanisms (Fig. 1) , each with its specific characteristics and regulators. 308 IMG occurs in various tumor types, and is increased in relapsing tumors after irradiation or antiangiogenic treatment. [309] [310] [311] [312] [313] [314] [315] In hepatocellular carcinoma xenografts treated with the mTOR inhibitor sirolimus, IMG was observed during treatment and early recovery phase, whereas in control animals the capillary plexus mainly extended by sprouting. 311 Similarly, treatment of mammary carcinomas in mice by radiation or the VEGFR inhibitor PTK787 resulted in transient reduction of tumor growth, followed by post-therapy relapse accompanied by IMG. 309 Comparable observations were made in the RIP-Tag2 and Lewis Lung carcinoma models treated with inhibitors of VEGFR signaling and in renal cell carcinoma 312 and melanoma models treated with TKIs. 316 These data suggest that IMG represents a tumor-protective response to cancer therapy to preserve the intratumoral vasculature. Moreover, the mechanism of IMG is very different from sprouting, indicating that other therapeutic strategies will have to be followed.
Vessel co-option mainly occurs in tumors and metastases of highly vascularized tissues (see Section 2.3). Treatment of mice bearing brain metastases of VEGF-overexpressing melanoma cells with the VEGFR2 TKI ZD6474
showed, despite effective blockage of angiogenesis, sustained tumor progression via co-option. 317 In glioblastomabearing mice, an anti-VEGF antibody prolonged survival but increased vascular co-option. 318 Also in an orthotopic human hepatocellular carcinoma (HCC) model, tumors resistant to sorafenib (the TKI approved for systemic therapy of HCC) became more invasive, which facilitated the co-option of liver vessels. Interestingly, whereas 24% of the total vessels were provided by co-option in untreated tumors, this number reached up to 75% in sorafenib-resistant tumors, thus providing the first evidence that vessel co-option is responsible for resistance to antiangiogenic therapy. 319 Also in melanoma metastases taken at clinical relapse in patients undergoing adjuvant treatment with bevacizumab, a mature intratumoral network with low angiogenic activity was noted. 320 Vessel co-option is also associated with resistance to sunitinib in preclinical lung metastasis models 75 and with a poor response to bevacizumab in patients with CRC liver metastases. 321 Moreover, combined inhibition of angiogenesis and vessel co-option was found to be more effective than the inhibition of angiogenesis alone. 321 
Vascular independence of tumor cells
A prerequisite for the anticancer potential of antiangiogenic agents is the vascular dependence of tumors. However, recent data indicate that tumor cells are heterogeneous in their dependence on neighboring tumor-associated vasculature for survival. Some cancer cells are highly vessel dependent, whereas others can survive in more hypoxic regions of tumors, distal from tumor vessels. Moreover, long-term antiangiogenic therapy may result in the outgrowth of subpopulations of less angiogenesis-dependent malignant cells with an increased capacity to survive in nutrient-or oxygendeprived tumor areas. 322, 323 Several mechanisms may account for the vascular independence of tumor cells. It has been reported that mice bearing p53-deficient (p53 −/− ) HCT116 human CRC tumors are less responsive to antiangiogenic combination therapy than mice bearing isogenic p53 +/+ tumors. 324 Alternatively, a metabolic switch in cancer cells may occur, as reported in a mouse model of breast cancer treated with the TKIs nintedanib or sunitinib. After an initial regression, tumors became resistant and resumed growth in the absence of tumor angiogenesis. Distal cells located in avascular areas underwent metabolic reprogramming toward a hyperglycolytic state producing lactate, which was utilized by tumor cells in the vicinity of blood vessels for oxidative phosphorylation. 325 Altogether these observations confirm that, even if antiangiogenic therapy targets genetically stable ECs in the tumor vasculature, genetic alterations or metabolic switches that decrease the vascular dependence of tumor cells can influence the therapeutic response of tumors to this therapy.
Hypoxia induces a more aggressive and resistant tumor type
Hypoxia is one of the main features of solid tumors, and correlates with poor prognosis of cancer patients. 326 Reduced oxygenation of the tumor tissue is also acknowledged as a main cause of resistance to chemo-and radiotherapy. Intratumoral hypoxia can confer chemoresistance by (i) affecting drug delivery and cellular uptake through associated acidity, (ii) upregulation of multidrug resistance protein (MDR) expression, or (iii) by the fact that a number of chemotherapeutics require oxygen to exert their cytotoxic activity. 327 Resistance to radiotherapy is mainly caused by reduced generation of reactive oxygen species (ROS) and decreased DNA damage. 328 In general, radio-and chemotherapy preferentially target rapidly proliferating tumor cells. However, the most resistant cells are quiescent, slowly proliferating, stem-like cell fractions residing in the most hypoxic tumor region. 329, 330 The original paradigm of tumor growth stated that tumors cannot survive or grow in conditions of hypoxia, such as induced by antiangiogenic therapy. However, after treatment with VEGF blockers a proportion of hypoxiatolerant cancer cells survives in poorly oxygenated niches and adapts to antiangiogenesis by increasing various cellular survival processes. 331 Moreover, dysfunctional tumor vascularity and heterogenic blood supply cause oxygen fluctuations with sporadic reoxygenation periods in cancer. 332 Cells reoxygenated after acute hypoxia may undergo rapid p53-dependent apoptosis. Consequently, cells that lack functional p53 are even more prone to further genomic instability, and potentially tumorigenesis, if they experience reoxygenation after acute exposure to hypoxia. 333 Hypoxia results in the activation of HIFs. These transcription factors are master regulators of O 2 homeostasis that mediate many transcriptional changes in response to low O 2 tension. HIF-1 consists of a constitutively expressed subunit and an O 2 -sensitive subunit that is rapidly degraded in normoxic conditions. Degradation involves recognition by prolyl hydroxylase domain (PHD) enzymes, binding to the von Hippel-Lindau (VHL) tumor suppressor protein, ubiquitination, and proteasomal degradation. 334 Under hypoxic conditions, PHD activity is attenuated, leading to HIF-1 protein stabilization, dimerization with HIF-1 , and translocation into the nucleus. The binding of the HIF-1 / heterodimer to hypoxia response elements (HREs) subsequently induces the transcriptional activation of various genes involved in angiogenesis, metastasis, apoptosis, and glycolysis. 335 As an example, in clear cell renal carcinoma loss of function of the VHL gene, which is responsible for ubiquitination and degradation of HIF-1 , leads to the upregulation of HIF responsive genes, such as PDGF and VEGF. 336 Nevertheless, the HIF pathway can also be activated in a hypoxia-independent manner by epigenetic changes and mutations that lead to a loss of tumor-suppressor functions and/or a gain of oncogene functions, or in response to cytokines and growth factors. 337 It is worth to remember that HIF-1 and nuclear factor kappa B (NF B) together govern the malignant and metastatic phenotype of cancer cells through the regulation of a plethora of genes involved in cell survival, migration, invasion, metabolism, and neovascularization. 338 Overall, hypoxia induces an imbalance in the production of pro-and antiangiogenic factors, which leads to enhanced, rapid, and chaotic blood vessel formation. In particular, hypoxia and HIF-1/2 have been shown to be directly involved in all steps of blood vessel formation. Hypoxia induces the recruitment of EPCs from the bone marrow and their differentiation into ECs. 339 HIF-1/2 stimulate EC proliferation and sprouting of preexisting vessels.
Also, HIF1/2 support vessel maturation by inducing Ang-1, PDGF, and TGF-that recruit smooth muscle cells and pericytes. 340 Intratumoral neovessels are often abnormal, immature, and leaky, and expanding tumors are extremely demanding in terms of nutrients and oxygen. This results in an hypoxic/angiogenic loop generating a tumor tissue that is highly hypoxic and that contains an excessive/dysfunctional vasculature. 341 
Side effects associated with antiangiogenic therapies
Since antiangiogenic compounds are thought to specifically target newly formed, rather than existing vessels or other normal cell types, no or only minor toxicity was anticipated. However, the expanding use of drugs targeting the VEGF signaling pathway in cancer unveiled that these antiangiogenic treatments are often associated with a wide spectrum of toxicities. 342, 343 Meta-analyses demonstrated a small risk, around 1.5-2.5% of fatal adverse events with both antiangiogenic TKIs and bevacizumab.
Some adverse effects are shared with conventional chemotherapeutic agents while others are unique and not typically observed with cytotoxic drugs. Specific toxicities associated with VEGF axis inhibition using VEGF-ligand or VEGFR inhibitors include cardiovascular effects (hypertension, thromboembolism, left ventricular dysfunction, cerebrovascular effects) as well as noncardiovascular effects (proteinuria, bleeding/hemorrhage, delayed wound healing, gastrointestinal perforation, fatigue, and dysphonia). [343] [344] [345] [346] Other rare class effects of VEGF axis inhibition comprise reversible posterior leukoencephalopathy (RPLS), osteonecrosis of the jaw (ONJ), and microangiopathic hemolysis.
One study associated bevacizumab with increased risk of death in combination with taxanes or platinum agents but not in combination with other agents. 342 The antiangiogenic TKIs display additional class-related toxicities, including gastrointestinal events (diarrhea, nausea), thyroid dysfunction, fatigue, stomatitis, myelosuppression, and cutaneous effects. 347, 348 Some of these side effects may reflect the promiscuity of kinase inhibitors, which inhibit multiple other receptors in addition to
VEGFRs.
Other drugs like thalidomide, lenalidomide, and pomalidomide, which have both immunomodulatory and antiangiogenic activity, are associated with thrombotic complications, especially when combined with glucocorticoids and/or cytotoxic chemotherapy.
Ways to improve antitumor efficacy of antiangiogenic therapy

Specific targeted therapy versus multitarget compounds-monotherapy versus combination therapy
The prototype of specific/targeted therapies is a monoclonal antibody (mAb), which is usually designed against a very specific target to avoid side effects. Besides bevacizumab, which targets VEGF, some mAbs exhibit antiangiogenic functions due to crosstalk between the signaling pathways that involve VEGF and other growth factors. This is the case for anti-EGFR/HER antibodies, such as cetuximab (Erbitux), trastuzumab (Herceptin), and panitumumab (Vectibix). 349 One of the main drawbacks of this targeted approach is that it often leads to drug resistance, for example, bevacizumab monotherapy induces a rapid reboost in metastatic patients. A less selective molecule aflibercept (AVE0005, Zaltrap) functions as a soluble "decoy" VEGF-trap receptor, preventing the binding of VEGF, VEGF-B, and PIGF to the cell surface receptors. Its wider binding spectrum, when compared with bevacizumab, improved progression-free survival, and overall survival in a clinical trial involving metastatic CRC. 350 Unlike antibodies and ligand trap molecules, TKIs (Fig. 3, Table II ) cross the cell membrane and interact directly with the intracellular domain of receptors and/or other signaling molecules. Due to similarities in the kinase domains, most TKIs offer multitarget activity, good response, and sometimes improved survival rates in phase III clinical trials. 351 VEGFR inhibitors, like axitinib, pazopanib, sunitinib, vandetanib, and vatalanib, block also other receptors, such as PDGFR, c-Kit, EGFR, or RET. Moreover, the VEGFR inhibitor sorafenib targets PDGFR, c-Kit, Flt-3, and BRAF, while sunitinib inhibits Flt-3 and CSF-1R, and nintedanib (BIBF1120) blocks VEGFR, PDGFR, and FGFR signaling. 352 Interestingly, in contrast to agents like bevacizumab and aflibercept that show greater activity when combined with chemotherapy, TKIs generally display single agent activity.
Nevertheless, TKIs have also been investigated in combination with chemotherapy, especially in advanced NSCLC, showing clinical benefits in some studies, but failing to prolong overall survival in others. 353, 354 In general, given the role of PDGFR, FGFR, and others RTKs in various aspects of tumor biology, especially regarding pericyte and tumorcell function, it is difficult to assess the contribution of individual targets to the clinical activity of the multitarget agents. However, preclinical data provided evidence that cotargeting signaling by multiple proangiogenic factors is necessary to obtain an efficient and durable effect on tumor angiogenesis and growth, implying that multitarget inhibition might be a promising anticancer strategy. As an example, anti-VEGF therapy combined with the endogenous tumstatin peptide (that binds to v 3 integrin) delayed tumor growth in human renal cell carcinoma xenografts only when administered together. 384 Combination therapies with specific or multitargeting antiangiogenics may involve chemotherapy, radiotherapy, vascular-disrupting agents (VDAs), immunotherapy, or any other new approach. In particular, the use of chemotherapeutics together with antiangiogenic drugs has been widely explored and is actually a "hot topic" mainly in view of vascular normalization and metronomic chemotherapy (better described later herein).
VDAs target the already existing vessels in the tumor environment, thereby provoking a rapid collapse of the tumor vasculature leading to necrosis at the tumor core (reviewed in 385 ) . The clinical success of VDAs depends on the elimination of the viable tumor rim that is resistant to these compounds. This can be achieved by combination with Tumor angiogenesis also influences immune suppression, and angiogenic factors regulate immune cell trafficking across tumor endothelia. 387 For this reason targeting angiogenesis may be an effective approach to increase the efficacy of different types of immunotherapy, including immune checkpoint blockade. 388 Adoptive T-cell transfer in mice bearing large melanomas in combination with an anti-VEGF antibody significantly augmented antitumor activity and trafficking of T cells into the tumors. 389 The combination of CTLA4 blockade (ipilimumab) with bevacizumab improved survival of metastatic melanoma patients. This result was associated with endothelial activation and extensive CD8 + and macrophage cell infiltration. 390 Several trials in melanoma are ongoing combining bevacizumab and immunotherapy with anti-PD1 (Nivolumab and MK-3475), anti-PDL1 (Atezolizumab), or anti-CTLA4 (Ipilimumab) antibodies. 390, 391 In addition, the combination of anti-Ang-2 (MEDI3617) and anti-CTLA4 (tremelimumab) antibodies, as well as of pembrolizumab (anti-PD1) and Ziv-Aflibercept are in clinical evaluation for patients with melanoma or advanced solid tumors, respectively. 391 These studies will provide the basis for further investigations regarding the interactions among angiogenic factors, blood vessel formation, immune regulation, and microenvironment, eventually paving the way for therapeutic exploitation of new drug combinations.
Concept of vessel normalization versus regression
The tumor vasculature is characterized by increased vessel permeability and high interstitial fluid pressure as a consequence of its tortuous and chaotic structure, scarce pericyte coverage, and discontinuous BM. Instead of vascular disruption, vessel normalization aims to increase partial oxygen pressure and perivascular cell coverage in the tumor.
This can be obtained through pruning and remodeling of abnormal tumor vessels, leading to vessels resembling normal tissue vasculature in terms of structure and function (Fig. 4) . 9 Preclinical studies have shown that anti-VEGF therapy and other antiangiogenic agents can induce vessel normalization. 10, 392 In patients, bevacizumab monotherapy was found to induce an increase in pericyte coverage, indicative of vascular normalization. Moreover, bevacizumab improved response to chemotherapy, especially in patients with a high pretreatment MVD, suggesting that this approach is only beneficial in highly vascularized tumors. 393 Many examples of vascular normalization targets are available. Tie2 activation (by Ang-2-binding and Tie2-activating antibody) reduced tumor growth and metastasis by inducing tumor vascular normalization, increasing blood perfusion, and favoring chemotherapeutic drug delivery. 394 Dual inhibition of VEGFR/Ang-2 (using cediranib and MEDI3617) improved survival in orthotopic models of glioblastoma via enhanced vessel normalization and polarization of TAMs to antitumor phenotypes. 395 Pharmacological inhibition of the HGF receptor c-Met normalized vessels formed in vitro by GBM tumor-derived ECs. 396 Preclinical studies suggest that anti-VEGFR2 antibody (DC101) treatment can normalize orthotopic tumor vasculature and enhance the delivery of anticancer agents. 397, 398 Moreover, inhibition of oncogenic signaling may indirectly trigger vascular normalization. Blocking HER-2 signaling in breast cancer cells with the mAb trastuzumab (Herceptin) normalized breast tumor vessels by modulating the expression of at least four pro-and antiangiogenic molecules. 392 The early antitumor responses of castration in androgen-dependent carcinomas are primarily vascular effects due to an indirect mechanism where hormone depletion suppresses tumor cell production of angiogenic factors. 399 Suppression of BRAF signaling by PLX4720 diminished the expression of several proangiogenic factors downstream of BRAF, which in turn stabilized vessel architecture, improved perfusion, and abrogated hypoxia. 400 Recently, chloroquine has been shown to induce vascular normalization and reduce metastasis by enhancing Notch signaling in ECs. 401 Several other studies convincingly reported similar "normalizing" effects as a consequence of tumor cell oncogene (Ras, PI3K, AKT, EGFR) inhibition. 402 These findings are supportive of the vascular normalization hypothesis proposed by Jain 61 that tumor blood vessels can revert from their abnormal phenotype to one more resembling normal tissues through restoration of the balance between pro-and antiangiogenic factors.
However, it should be taken into account that the benefits of vascular normalization are dose and time dependent. 403 Thus, optimizing combinations of antiangiogenic agents with anticancer treatments will require the assessment of imaging and/or circulating biomarkers to understand the dynamics of the tumor vascular response and the balance between vascular normalizing and antivascular effects.
Additional targets and approaches
FGF/FGFR system. Additional angiogenesis regulators are emerging to target in combination with, or in response to, resistance to anti-VEGF blockade. One of these targets is represented by the FGF/FGFR system, which is activated in a variety of human tumors, leading to neovascularization, tumor progression, and metastatic dissemination. Efforts have been made to develop efficacious FGF/FGFR inhibitors for antiangiogenic/antitumor therapies (Fig. 3 , Table II ).
These include selective and nonselective small-molecule TKIs, anti-FGFR antibodies, and some extracellular FGF ligand traps. 404, 405 Several wide-spectrum/nonselective TKIs block FGFRs with therapeutic efficacy (see 406, 407 for more details). Regorafenib is a novel orally active multitarget compound that inhibits a number of proangiogenic RTKs, including FGFR1, VEGFR2, Tie2, and PDGFR. 408 Nintedanib (BIBF1120) interferes with VEGFR, PDGFR, and FGFR pathways. 409 All these multitargeting TKIs are endowed with toxicity profiles often related to their anti-VEGFR action.
Few selective FGFR inhibitors have been characterized and evaluated in clinical trials, like AZD4547 and LY287445
(pan-FGFR inhibitors) and BGJ398 (that targets FGFR1, FGFR2, and FGFR3). These new "FGFR-restricted" drugs show better tolerability compared to nonselective TKIs. Their most relevant side effects (hyperphosphatemia and tissue calcification) are strictly correlated to the inhibition of the FGF23 pathway. Apart from TKIs, the small-molecule SSR128129E binds extracellularly to FGFRs and inhibits FGFR signaling by an allosteric mechanism of action, without affecting orthosteric FGF binding. 364 Finally, several FGF traps have been described. FP-1039 is a soluble FGFR1(IIIc)-Fc fusion protein that binds and inhibits almost all FGFs and has entered clinical trials, 362 whereas the long pentraxin-3 (PTX3)-derived small drug NSC12 represents the first low molecular weight FGF trap. 363 Interestingly, at variance with the hyperphosphatemic effect of FGFR TKIs, administration of FGF traps (FP-1039 and NSC12) does not affect blood levels of phosphorus, calcium, and FGF23, and shows a safe profile in murine tumor models. 416, 417 Further clinical development of these hypoxia-targeting agents will require (i) improvement of direct and indirect methods to measure hypoxia in vivo and to select patients who could benefit from this therapy, as well as (ii)
defining the appropriate treatment schedule.
Vascular targeting.
An alternative therapeutic strategy to angiogenesis inhibitors, which block neovascularization, is represented by "vascular targeting," 418 which relies on mAbs that recognize specific markers on newly formed blood vessels or in the stroma surrounding these vessels. These Abs selectively deliver potent therapeutic payloads (such as drugs, cytokines, radionuclides, photosensitizers, and toxins) to disease sites where neoangiogenesis takes place. 419, 420 Several antigens have been identified using immunohistochemical, proteomic, or transcriptomic screenings. 421, 422 Well-known examples are represented by the alternatively spliced extradomains A and B of fibronectin, as well as the extradomain A1 of tenascin-C. These splice variants are undetectable in normal adult tissues but become strongly expressed at sites of physiological and tumor angiogenesis. 423, 424 Another marker of angiogenesis, the lipid raft associated protein bone marrow stromal antigen-2 (Bst-2) appears to be more restricted to hematological malignancies like lymphomas. 425 To date, antibody-drug conjugates (ADC) and immunocytokines are advancing in clinical trials, 426 the latter with promising results, warranting efforts to precisely characterize their mechanisms of action.
Targeting EC metabolism. Recently, Carmeliet and co-workers postulated the concept that EC metabolism represents the engine of ECs, onto which proangiogenic signals (such as VEGF) converge. 427 As a consequence, whereas tumors develop resistance to treatment directed at specific proangiogenic proteins, targeting metabolic pathways may block the activation of ECs that are exposed to multiple angiogenic mediators (see also Section 3.4). The potential of this novel approach has recently been illustrated in several elegant studies.
Antiglycolytic therapy with a small molecule blocker of PFKFB3 (3PO) exerted convincing antiangiogenic effects in different in vitro and in vivo models. Interestingly, a partial and transient reduction of glycolysis by blockade of PFKFB3 seems to be sufficient to decrease pathological neovascularization. 278 Moreover, blockade (or genetic deficiency) of PFKFB3 results in inhibition of cancer cell invasion and metastasis. This effect is mainly due to increased tumor vessel normalization, improved vessel maturation, and perfusion. Indeed, PFKFB3 inhibition lowers the expression of cancer cell adhesion molecules in ECs, tightens the vascular barrier by reducing VE-cadherin endocytosis, and renders pericytes more quiescent and adhesive. 428 In addition, recent findings identified FOXO1 as a major regulator of vascular activation. In particular, the FOXO1-MYC transcriptional axis emerged as a critical metabolic checkpoint for EC proliferation and as a new target for antiangiogenic therapies. 286 Also FA metabolism and nucleotide synthesis might present potential therapeutic antiangiogenic targets. CPT1A
silencing depletes EC stores of aspartate and dNTPs, and pharmacological blockade of CPT1 by etomoxir (an irreversible inhibitor of mitochondrial long-chain FAO) inhibits pathological ocular angiogenesis in mice. 289 Thus, targeting EC metabolism represents an emerging therapeutic option as new targets are being identified and/or under characterization.
CONCLUSION
Almost 50 years of angiogenesis research have resulted in increasingly more complex insights into tumor vascularization. These insights have provided novel hypotheses and concepts that may explain the disappointing anticancer efficacy of VEGF/VEGFR targeted agents in the clinic, and may pave the way for improved antiangiogenic cancer treatment.
First, a major part of the complexity in antiangiogenic therapy can be ascribed to the various mechanisms used by tumors to increase their blood supply (Fig. 1) . 2 These modes of vascularization may coexist within a tumor, 60 but tumors may also shift from one mechanism to another during growth and metastasis, and in response to treatment. 75, 309, 321 Whereas sprouting angiogenesis has been investigated intensively, the study of these alternative modes of vascularization faces several problems. Cellular and molecular mediators of these vascularization mechanisms are poorly defined. Intratumoral vessels derived from VM are morphologically indistinguishable from normal blood vessels. Also, markers that unambiguously distinguish angiogenic versus co-opted vessels are lacking. The extent to which EPCs and CSCs contribute to tumor vascularization is unclear in part because of the lack of a consensus definition of these cell types. Because of these limitations, information is lacking regarding the relative contribution of blood vessels derived from these different vascularization modes in tumors.
A second obstacle to the clinical use of antiangiogenic drugs is the emergence of tumor resistance. Although antiangiogenic agents were anticipated to target genetically stable cells (i.e., ECs) that lack the capacity to rapidly adapt to treatment, various tumor escape mechanisms have been observed. Tumors respond to treatment with VEGF/VEGFRtargeted drugs by the expression and activation of alternative angiogenic factors and pathways. 292, 294 Moreover, antiangiogenic treatment has been shown to select for hypoxia-tolerant 331 or vessel-independent tumor cells 323 or a tumor vasculature that arises in the absence of angiogenesis. 319 Thus, blocking angiogenesis may lead to the occurrence of more aggressive tumor cells and increased metastasis.
Third, the identification of novel mediators of angiogenesis has further diversified the angiogenesis landscape and has complicated target selection. Molecular and functional analyses of sprouting angiogenesis have uncovered a link between neuronal guidance and tip cell sprouting. 3, 4 Similarly, anti-and proangiogenic functions have been ascribed to various proteins involved in bone homeostasis. 5 Emerging avenues further include the diverse functions elicited by microRNAs 6 and the role of EC metabolism in angiogenesis. 7 In particular, the latter is increasingly being recognized as a key determinant of angiogenesis regulation. Recent in vivo studies showed that a partial and transient reduction of the glycolytic enzyme PFKFB3 is sufficient to induce endothelial quiescence without affecting glycolysis required for normal cell maintenance. 278 This opens perspectives for the development of novel nontoxic antiangiogenic therapies. However, to date few metabolic enzymes have been studied in ECs. Research has mainly focused on the relation between a specific metabolic pathway and angiogenesis, and insights into the role of different metabolic pathways in angiogenesis are lacking. Moreover, the interactions between ECs and the tumor microenvironment should be considered. Stromal and tumor cells, but also viruses and bacteria that reside in the tumor microenvironment may compete with ECs for nutrient and/or metabolite usage.
The major question that remains is: how can the recently acquired knowledge be translated to improved anticancer efficacy of antiangiogenic agents? The answer lies not only in a better understanding of the mechanisms of action and resistance of currently used anti-VEGF agents, but also in a better selection of the patient population. Antiangiogenic drugs have predominantly been tested in unselected patients with large tumors. However, since these agents are in general not cytotoxic, the treatment of small tumors might provide more favorable results. Related to this point, therapy would greatly benefit from the identification of biomarkers that can predict which patients are likely to respond to a given therapy. Considering the multifactorial nature of neovascularization, which involves a variety of cell types and mediators, it is unlikely that targeting a single angiogenic factor will afford a protective effect. Future therapies should tackle the process at different levels by using multitarget compounds or by blocking EC metabolism, which may overrule signals transmitted by various growth factors. Studies should also focus on the elucidation of the genetic basis of tumor vessel normalization, in order to prevent the selection of more aggressive tumor cell clones and to improve the delivery and/or activity of radio-and chemotherapy. Thereby, it should be taken into consideration that in the tumor, not only the blood vessels, but also other components of the tumor microenvironment are abnormal. Thus, therapeutic agents should normalize the entire tumor microenvironment, including cancer-associated fibroblasts and protumor immune cells. All together, these future insights may boost the development of totally new classes of compounds and/or treatment schedules with hopefully improved clinical anticancer efficacy.
